. 2014 Feb 25;74(4):423–441. doi: 10.1007/s40265-014-0191-y

Table 4.

Traditional disease-modifying anti-rheumatic drugs (DMARDs) and currently available biologics: clinical effects in psoriatic arthritis (PsA)

Drug	Evidence for beneficial impact on PsA (+ or −)
Drug	Signs/symptoms	Radiographic damage/progression	Enthesitis	Dactylitis	Axial involvement
Methotrexate [105–108]	−	Inconclusive	Unknown	Unknown	−
Sulfasalazine [109–111]	+	−	−	−	−
Leflunomide [112–114]	+	Unknown	Unknown	Unknown	−
Cyclosporine A [115–117]	+	Unknown	Unknown	Unknown	−
Biologics
Anti-TNF-α antibodies [2]	+	+	+	+	Unknown^a
Etanercept [125, 126]	+	+	+	+	Unknown^a
Infliximab [118, 119]	+	+	+	+	Unknown^a
Adalimumab [120, 121]	+	+	Inconclusive	Inconclusive	Unknown^a
Golimumab [122, 123]	+	+	+	+	Unknown^a
Certolizumab pegol [127, 128]	+	+	+	+	Unknown^a
Anti-IL-12/23 antibody
Ustekinumab [124, 202]	+	+	+	+	Unknown

IL interleukin, TNF tumour necrosis factor

^aThe efficacy of anti-TNF-α antibodies in axial involvement has not been directly evaluated in PsA trials. Treatment responses reported in ankylosing spondylitis are used to indicate efficacy in this condition [129]